Myriad Genetics, Inc. Stock

$5.83

5.43% yesterday

Nasdaq, Aug 21, 10:00 pm CET

ISIN

US62855J1043

Symbol

MYGN

Reports

Quarter | Annual

Index

NASDAQ Composite, S&P SmallCap 600

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Myriad Genetics, Inc. Stock price

$5.83

-8.64 59.71% 5Y

Nasdaq, Closing price Thu, Aug 21 2025

+0.30 5.43%

ISIN

US62855J1043

Symbol

MYGN

Reports

Quarter | Annual

Index

NASDAQ Composite, S&P SmallCap 600

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$514.5m

Enterprise Value

Net debt

Cash

Shares outstanding

Valuation (TTM | estimate)

P/E

negative | negative

P/S

0.6 | 0.6

EV/Sales

- | -

EV/FCF

P/B

Financial Health

Equity Ratio

68.2%

Return on Equity

-18.2%

ROCE

ROIC

Debt/Equity

Financials (TTM | estimate)

Revenue

$832.9m | $826.4m

EBITDA

$-17.7m | $21.0m

EBIT

$-76.6m | $-1.4m

Net Income

$-395.2m | -

Free Cash Flow

$-47.7m

Growth (TTM | estimate)

Revenue

3.8% | -1.3%

EBITDA

58.4% | 178.2%

EBIT

25.3% | 98.4%

Net Income

-154.6% | -

Free Cash Flow

66.8%

EPS

$-4.3

FCF per Share

Short interest

12.8%

Employees

Rev per Employee

$310.0k

As a Free StocksGuide user, you can view scores for all 7,014 stocks worldwide.

Get Started for Free Today

Myriad Genetics, Inc. Stock Analysis

Unlock Scores for Free

??

21 Analysts have issued a Myriad Genetics, Inc. forecast:

11x Hold

52%

7x Sell

33%

More details on Analyst Estimates Including Price Targets

21 Analysts have issued a Myriad Genetics, Inc. forecast:

Buy

14%

Hold

52%

Sell

33%

Analyst Estimates with Stock Price Targets

Financial data from Myriad Genetics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '25		+/- %
Revenue	833 833	4% 4% 100%
- Direct Costs	246 246	1% 1% 30%
Gross Profit	587 587	6% 6% 70%
- Selling and Administrative Expenses	550 550	2% 2% 66%
- Research and Development Expense	114 114	17% 17% 14%
EBITDA	-18 -18	58% 58% -2%
- Depreciation and Amortization	59 59	2% 2% 7%
EBIT (Operating Income) EBIT	-77 -77	25% 25% -9%
Net Profit	-395 -395	155% 155% -47%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Myriad Genetics, Inc. Stock News

Positive

Proactive Investors

●

2 days ago

ANGLE partners with Myriad Genetics on enhanced patient treatment approach in cancer

ANGLE PLC (AIM:AGL, OTCQX:ANPCY) has struck a collaboration with Myriad Genetics of the US to explore whether cancer DNA captured from blood can be used alongside existing tumour tissue tests. The liquid biopsy specialist said on Wednesday that blood samples from cancer patients would be processed using its Parsortix system, which isolates whole cancer cells circulating in the bloodstream.

Neutral

GlobeNewsWire

●

4 days ago

Myriad Genetics Appoints Ben Wheeler Chief Financial Officer

SALT LAKE CITY, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Ben Wheeler has been promoted to Chief Financial Officer, effective August 16, 2025.

Neutral

GlobeNewsWire

●

9 days ago

New Myriad Genetics Survey Uncovers Women Fear Screenings—But Feel Reassured by the Results

Cancer Risk Survey shows that more than half of women at high-risk for hereditary cancer would feel "empowered" by more advanced screening like genetic testing Cancer Risk Survey shows that more than half of women at high-risk for hereditary cancer would feel "empowered" by more advanced screening like genetic testing

More Myriad Genetics, Inc. News

Company Profile

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic test. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to asses an individual's risk of developing a disease later in life. The Other segment offers products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients; and also includes corporate services such as finance, human resources, legal, and information technology. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Head office	United States
CEO	Samraat Raha
Employees	2,700
Founded	1991
Website	myriad.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now